Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) EBITDA (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed EBITDA for 6 consecutive years, with -$13.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 6.55% to -$13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$52.0 million through Dec 2025, down 81.8% year-over-year, with the annual reading at -$52.0 million for FY2025, 81.8% down from the prior year.
  • EBITDA for Q4 2025 was -$13.8 million at Inhibikase Therapeutics, down from -$12.8 million in the prior quarter.
  • The five-year high for EBITDA was -$2.6 million in Q1 2021, with the low at -$14.6 million in Q1 2025.
  • Average EBITDA over 5 years is -$6.7 million, with a median of -$4.7 million recorded in 2023.
  • The sharpest move saw EBITDA tumbled 573.64% in 2021, then increased 15.05% in 2024.
  • Over 5 years, EBITDA stood at -$5.0 million in 2021, then grew by 14.01% to -$4.3 million in 2022, then fell by 1.58% to -$4.4 million in 2023, then crashed by 193.6% to -$12.9 million in 2024, then decreased by 6.55% to -$13.8 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$13.8 million, -$12.8 million, and -$10.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.